1.

Oropharyngeal carriage of macrolide-resistant viridans group streptococci: a prevalence study among healthy adults in Belgium

2.

Oropharyngeal carriage of macrolide-resistant viridans group streptococci: a prevalence study among healthy adults in Belgium

3.

Oropharyngeal carriage of macrolide-resistant viridans group streptococci: a prevalence study among healthy adults in Belgium

4.

Oropharyngeal carriage of macrolide-resistant viridans group streptococci: a prevalence study among healthy adults in Belgium

5.

Oropharyngeal carriage of macrolide-resistant viridans group streptococci: a prevalence study among healthy adults in Belgium

1.

Complete sequence of an IncFII plasmid harbouring the colistin resistance genemcr-1isolated from Belgian pig farms

1.

Bacitracin-Resistant Clone of Streptococcus pyogenes Isolated from Pharyngitis Patients in Belgium

1.

Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10

2.

Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10

3.

Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10

4.

Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10

5.

Increase in fluoroquinolone non-susceptibility among clinical Streptococcus pyogenes in Belgium during 2007-10

1.

Antimicrobial Drug Use and Macrolide-Resistant Streptococcus pyogenes, Belgium

2.

Antimicrobial Drug Use and Macrolide-Resistant Streptococcus pyogenes, Belgium

3.

Antimicrobial Drug Use and Macrolide-Resistant Streptococcus pyogenes, Belgium

1.

No SARS‐CoV‐2 carriage observed in children attending daycare centers during the intial weeks of the epidemic in Belgium

1.

Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–2003

1.

Remarkable Genome Stability among emm1 Group A Streptococcus in Belgium over 19 Years

1.

Increase in bloodstream infections caused by emm1 group A Streptococcus correlates with emergence of toxigenic M1UK, Belgium, May 2022 to August 2023.

2.

Increase in bloodstream infections caused by emm1 group A Streptococcus correlates with emergence of toxigenic M1UK, Belgium, May 2022 to August 2023.

3.

Increase in bloodstream infections caused by emm1 group A Streptococcus correlates with emergence of toxigenic M1UK, Belgium, May 2022 to August 2023.

1.

Nasopharyngeal s. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme